Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.
نویسندگان
چکیده
BACKGROUND Hereditary angioedema is characterized by recurrent attacks of angioedema of the skin, larynx, and gastrointestinal tract. Bradykinin is the key mediator of symptoms. Icatibant is a selective bradykinin B2 receptor antagonist. METHODS In two double-blind, randomized, multicenter trials, we evaluated the effect of icatibant in patients with hereditary angioedema presenting with cutaneous or abdominal attacks. In the For Angioedema Subcutaneous Treatment (FAST) 1 trial, patients received either icatibant or placebo; in FAST-2, patients received either icatibant or oral tranexamic acid, at a dose of 3 g daily for 2 days. Icatibant was given once, subcutaneously, at a dose of 30 mg. The primary end point was the median time to clinically significant relief of symptoms. RESULTS A total of 56 and 74 patients underwent randomization in the FAST-1 and FAST-2 trials, respectively. The primary end point was reached in 2.5 hours with icatibant versus 4.6 hours with placebo in the FAST-1 trial (P=0.14) and in 2.0 hours with icatibant versus 12.0 hours with tranexamic acid in the FAST-2 trial (P<0.001). In the FAST-1 study, 3 recipients of icatibant and 13 recipients of placebo needed treatment with rescue medication. The median time to first improvement of symptoms, as assessed by patients and by investigators, was significantly shorter with icatibant in both trials. No icatibant-related serious adverse events were reported. CONCLUSIONS In patients with hereditary angioedema having acute attacks, we found a significant benefit of icatibant as compared with tranexamic acid in one trial and a nonsignificant benefit of icatibant as compared with placebo in the other trial with regard to the primary end point. The early use of rescue medication may have obscured the benefit of icatibant in the placebo trial. (Funded by Jerini; ClinicalTrials.gov numbers, NCT00097695 and NCT00500656.)
منابع مشابه
Treatment of angiotensin-converting enzyme inhibitor related angioedema with icatibant
Background The absolute risk of angiotensin-converting enzyme (ACE) inhibitor angioedema is 0.3% [1]. The mechanism is felt to be accumulation of bradykinin. The current treatment is discontinuation of ACE-I inhibitor, and intubation if necessary. Icatibant is a bradykinin receptor antagonist, useful in treating hereditary angioedema [2]. We present a patient from a Canadian center who had ACE-...
متن کاملAn evidence-based review of the potential role of icatibant in the treatment of acute attacks in hereditary angioedema type I and II
INTRODUCTION Icatibant, a first-in-class B2 bradykinin receptor antagonist, appears to have a favorable efficacy and safety profile for the treatment of acute attacks of hereditary angioedema in adults. AIMS To update the evidence and provide an overview of the available data on icatibant. EVIDENCE REVIEW Peer reviewed articles published and listed in Medline Search and published updated gu...
متن کاملTreatment of angiotensin receptor blocker-induced angioedema: A case series.
BACKGROUND Angiotensin II receptor antagonists have been proposed as a replacement therapy after the occurrence of either an angiotensin converting enzyme (ACE) inhibitor-induced angioedema or cough. However, recent studies indicate that angioedema is associated with elevated bradykinin levels in a small fraction of patients treated with angiotensin-II-receptor blockers, suggesting a common pat...
متن کاملSelf-administration of a novel subcutaneous bradykinin b2 receptor antagonist, icatibant, as an effective treatment option in patients with hereditary angioedema
Background Hereditary Angioedema (HAE) is a rare disease characterized by recurrent angioedema attacks involving larynx, abdomen, extremities and various body parts. The reactions are by and large self-limited, but potentially, could be fatal. Until recently, the only approved treatment in Canada is an intravenous C1-esterase inhibitor infusion. However, intravenous therapy can be challenging f...
متن کامل165 Early Versus Delayed Treatment of Swelling Attacks with Icatibant, a Bradykinin 2 Receptor Antagonist in Patients With Hereditary Angioedema due to C1-INH Deficiency
caused by autoantibodies against C1-INH (AAE type II). Reduced C1-INH activity leads to uncontrolled bradykinin formation and to angioedema symptoms. There is no established treatment for AAE. Replacement with plasma-derived C1-INH is effective in most patients with life-threatening attack; however, icatibant, a bradykinin B2 receptor antagonist, may represent an alternative treatment. Methods:...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- The New England journal of medicine
دوره 363 6 شماره
صفحات -
تاریخ انتشار 2010